

## Author Index Volume 24 (2012)

The issue number is given in front of the page numbers

- Adong, J.O., see Odongkara, B.M. (2) 103–113  
Adeniran, A., see Awodele, O. (2) 65–72  
Agbabiaka, T.B., see Wheway, J. (3) 163–169  
Akasiima, A., see Odongkara, B.M. (2) 103–113  
Alexander, G.C., see Paczynski, R.P. (3) 137–146  
Alotaibi, A., see Posadzki, P. (3) 147–161  
Amsterdam, J.D., L.B. McHenry, The paroxetine 352 bipolar trial: A study in medical ghostwriting (4) 221–231  
Aronson, J.K., Evaluation of pharmacological evidence for forensic purposes (1) 3–12  
Awodele, D.F., see Awodele, O. (2) 65–72  
Awodele, O., A. Adeniran and D.F. Awodele, Pharmacovigilance amongst Patent Medicine Vendors (PMVs) in Ekiti state, Nigeria (2) 65–72  
  
Bakry, S.H., A.F. Mustafa, A.S. Eldalo and M.A. Yousif, Knowledge, attitude and practice of health care workers toward Hepatitis B virus infection, Sudan (2) 95–102  
Berger, J.T., M.-B. Sten and D.C. Stockwell, Patient handoffs: Delivering content efficiently and effectively is not enough (4) 201–205  
Body, D., see Edwards, I.R. (1) 1–2  
Bose-Haider, B., see Gordon, M. (4) 207–214  
  
Caplan, L., L.M. Haverhals, Barriers and facilitators for preventing Adverse Drug Reactions of Long Latency: A qualitative study (2) 81–94  
Chinchilli, V.M., see Paczynski, R.P. (3) 137–146  
Cuvelier, L., P. Falzon, J.-C. Granry, M.C. Moll and G. Orliaguet, Planning safe anesthesia: The role of collective resources management (3) 125–136  
  
Dukes, G., Writing reports for the courts (1) 55–58  
  
Edwards, I.R., D. Body, Forensic Pharmacovigilance (1) 1–2  
Edwards, I.R., Considerations on causality in pharmacovigilance (1) 41–54  
Eldalo, A.S., see Bakry, S.H. (2) 95–102  
Ernst, E., see Posadzki, P. (3) 147–161  
Ernst, E., see Wheway, J. (3) 163–169  
  
Falzon, P., see Cuvelier, L. (3) 125–136  
Ferner, R.E., Toxicological evidence in forensic pharmacology (1) 13–21  
  
Gamirova, R.G., R.M. Shaimardanova and L.E. Ziganshina, Pharmacoepidemiology of antiepileptic drugs in children: Comparative analysis of efficacy and safety (3) 179–185

- Gordon, M., B. Bose-Haider, A novel system of prescribing feedback to reduce errors:  
A pilot study (4) 207–214  
Granry, J.-C., see Cuvelier, L. (3) 125–136
- Hartigan-Go, K., Presenting evidence for the court (1) 59–63  
Haverhals, L.M., see Caplan, L. (2) 81–94  
Healy, D., see Herxheimer, A. (1) 23–29  
Healy, D., see Persaud, N. (1) 31–35  
Herxheimer, A., D. Healy and D.B. Menkes, Case histories as evidence (1) 23–29  
Hill, R., see Savage, R.L. (4) 215–219
- Ihara, H., A cold of the soul: A Japanese case of disease mongering in psychiatry (2) 115–120
- Katende, J., see Odongkara, B.M. (2) 103–113  
Kruszewski, S.P., see Paczynski, R.P. (3) 137–146
- Labadie, J., Forensic pharmacovigilance and substandard or counterfeit drugs (1) 37–39  
Lexchin, J., Sponsorship bias in clinical research (4) 233–242
- McHenry, L.B., see Amsterdam, J.D. (4) 221–231  
Menkes, D.B., see Herxheimer, A. (1) 23–29  
Moll, M.C., see Cuvelier, L. (3) 125–136  
Muchunguzi, H.V., see Odongkara, B.M. (2) 103–113  
Mukasa, S., see Odongkara, B.M. (2) 103–113  
Mulongo, G., see Odongkara, B.M. (2) 103–113  
Muralidhar, S., A. Taneja and V. Ramesh, Patient safety culture-perception of health care  
workers in a tertiary care hospital (4) 191–199  
Mustafa, A.F., see Bakry, S.H. (2) 95–102  
Mwetwale, C., see Odongkara, B.M. (2) 103–113
- O'Malley, G.F., see Sawalha, A.F. (3) 171–177  
Odongkara, B.M., G. Mulongo, C. Mwetwale, A. Akasiima, H.V. Muchunguzi, S. Mukasa,  
K.V. Turinawe, J.O. Adong and J. Katende, Prevalence of occupational exposure  
to HIV among health workers in Northern Uganda (2) 103–113  
Orliaguet, G., see Cuvelier, L. (3) 125–136
- Paczynski, R.P., G.C. Alexander, V.M. Chinchilli and S.P. Kruszewski, Quality of  
evidence in drug compendia supporting off-label use of typical and atypical antipsychotic  
medications (3) 137–146  
Persaud, N., D. Healy, Epidemiological evidence in forensic pharmacovigilance (1) 31–35  
Posadzki, P., A. Alotaibi and E. Ernst, Adverse effects of aromatherapy: A systematic review  
of case reports and case series (3) 147–161  
Pouwels, K.B., K. van Grootheest, The rosiglitazone decision process at FDA and EMA.  
What should we learn? (2) 73–80
- Ramesh, V., see Muralidhar, S. (4) 191–199
- Savage, R.L., K. Star and R. Hill, Severe muscle symptoms with lipid-lowering agents may  
be confused with neurogenic claudication associated with spinal canal stenosis (4) 215–219  
Sawalha, A.F., G.F. O'Malley and W.M. Sweileh, Pesticide poisoning in Palestine:  
A retrospective analysis of calls received by Poison Control and Drug Information  
Center from 2006–2010 (3) 171–177

- Shaimardanova, R.M., see Gamirova, R.G. (3) 179–185  
Star, K., see Savage, R.L. (4) 215–219  
Sten, M.-B., see Berger, J.T. (4) 201–205  
Stockwell, D.C., see Berger, J.T. (4) 201–205  
Sweileh, W.M., see Sawalha, A.F. (3) 171–177
- Taneja, A., see Muralidhar, S. (4) 191–199  
Turinawe, K.V., see Odongkara, B.M. (2) 103–113
- van Grootheest, K., see Pouwels, K.B. (2) 73–80  
van Puijenbroek, E., Jerry Labadie, a life dedicated to vaccine safety (4) 189
- Wheway, J., T.B. Agbabiaka and E. Ernst, Patient safety incidents from acupuncture treatments: A review of reports to the National Patient Safety Agency (3) 163–169
- Yousif, M.A., see Bakry, S.H. (2) 95–102
- Ziganshina, L.E., see Gamirova, R.G. (3) 179–185